banner
3'-O-MOE-5Me-C(Bz)-2'-phosphoramidite
Inquiry

Cat. No.: X25-06-LY272

3'-O-MOE-5Me-C(Bz)-2'-phosphoramidite

Synonym: 1098233-10-3; N-[1-[(2R,3R,4R,5R)-5-[[Bis(4-methoxyphenyl)-phenylmethoxy]methyl]-3-[2-cyanoethoxy-[di(propan-2-yl)amino]phosphanyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]-5-methyl-2-oxopyrimidin-4-yl]benzamide; 3'-O-MOE-5Me-C(Bz)-2'-phosphoramidite

  • CAS Number: 1098233-10-3
  • Compound CID: 167312631
img
Product Size
50 mg; 100 mg; 250 mg; 500 mg
Price
Datasheet
MSDS
Properties
Description
3'-O-MOE-5Me-C(Bz)-2'-phosphoramidite is a phosphoramide compound with 3'-O-methoxyethyl and 5-methyl-substituted nucleotide structures, and is suitable as a key intermediate for the synthesis of RNA and DNA oligonucleotides.
Molecular Weight
924.03
Molecular Formula
C50H62N5O10P
Form
Solid
Purity
≥95.0%
Applications
3'-O-MOE-5Me-C(Bz)-2'-phosphoramidite can be used to synthesize modified nucleic acids for gene therapy and RNA interference research.
Publications
Publications (0)

Publications

×
Publications

Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.

As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.

*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.

  • You can upload up to 5 images or ZIP files, and the size of a single file may not exceed 5MB.
Related Products
Quick Links

About Us

CD BioGlyco is a leading biotechnology company specializing in glycobiology. We deliver high-quality products and services to support cutting-edge research worldwide.

Contact Us

  • For research and manufacturing partners only. Not intended for (direct) human or veterinary use.
Copyright © CD BioGlyco. All rights reserved.